Clinical Trial Update: Impact of Fecal Biotherapy (FBT) on Microbial Diversity in Patients With Moderate to Severe Inflammatory Bowel Disease [Phase 1]

View source ↗

Summary

Phase 1 study update evaluating the impact of fecal biotherapy (FBT) on gut microbial diversity in patients with Crohn's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Fecal Biotherapy (FBT) (fecal biotherapy)

Snippet

Sponsor: Beth Israel Deaconess Medical Center | Conditions: Crohn's Disease | Phase 1 | Status: COMPLETED